Publications by authors named "Jordan Cammarota"
Article Synopsis
- This study explores why canakinumab, a treatment for Still's disease, is prescribed to patients with SJIA and AOSD in the US, based on a review of patient charts from 2016 to 2018.
- The analysis involved 72 patients, emphasizing that many had previously tried other treatments but switched due to ineffectiveness or the availability of canakinumab.
- The main reasons for initiating canakinumab were its perceived effectiveness by physicians, previous treatment failures, convenient administration, and the potential to reduce steroid use.
Background: Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed to characterize the reasons for canakinumab initiation among patients with PFS, specifically, cryopyrin-associated periodic syndrome (CAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), TNF receptor-associated periodic syndrome (TRAPS) and familial Mediterranean fever (FMF).
Methods: Physicians retrospectively reviewed the medical charts of PFS patients prescribed canakinumab between 2016 and 2018.
Adalimumab, infliximab, and ustekinumab have been approved for patients with moderate-to-severe Crohn's disease in Japan. This study compared the relative efficacy and cost-effectiveness of adalimumab, infliximab, and ustekinumab in patients with Crohn's disease based on data from randomized controlled trials. Data were extracted from four phase 3 clinical trials: CHARM, NCT00445432, ACCENT I, and IM-UNITI.
View Article and Find Full Text PDF